<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets</title>
<style>
body { font-family: Arial, Helvetica, sans-serif; background:#0f1115; color:#e6e6e6; margin:0; padding:40px; }
.container { max-width:700px; margin:auto; background:#161a21; border-radius:10px; padding:32px; box-shadow:0 0 30px rgba(0,0,0,0.4); }
h1 { margin-top:0; color:#4da3ff; }
table { width:100%; margin-top:12px; border-collapse:collapse; }
th, td { text-align:left; padding:6px 8px; border-bottom:1px solid #2a2f3a; }
ul { margin-top:12px; padding-left:20px; }
.section { margin-top:24px; }
.small { margin-top:12px; font-size:13px; color:#999; }
a { color:#4da3ff; }
</style>
</head>
<body>
  <div class="container">
    <h1>Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets</h1>

    <table>
      <tr><th>Ticker</th><td>TPST</td></tr>
      <tr><th>Float</th><td>4.6 M</td></tr>
      <tr><th>IO</th><td>15.92%</td></tr>
      <tr><th>MC</th><td>31.3 M</td></tr>
      <tr><th>Extra Info</th><td>None</td></tr>
    </table>

    <div class="section">
      <strong>Summary</strong>
      <p>Tempest Therapeutics (NASDAQ: TPST) published a post-transaction strategic plan to advance a newly acquired portfolio of dual-targeting CAR-T and oncology assets using a capital-efficient, partner-funded approach. The company will prioritize TPST-2003, a dual-targeting CD19/BCMA CAR-T, with ongoing Phase 1 data expected from China and a planned registrational Phase 2b initiation in China by end-2026 and interim data in 2027 (development in China funded by a strategic partner). Tempest disclosed TPST-4003, an in vivo CD19/BCMA program intended to move the biology into a scalable modality and to be advanced via preclinical work and potential partner-funded investigator-initiated trials. Amezalpat is positioned as Phase 3-ready in first-line hepatocellular carcinoma with business-development pursued for pivotal development. TPST-1495 is slated for an NCI-funded Phase 2 in familial adenomatous polyposis with first patient expected in Q1 2026. The company also plans to progress additional next-generation CAR-T candidates (TPST-3003, TPST-2206, TPST-3206). The release emphasizes reliance on external funding/partners and lists typical clinical, funding and regulatory risks.</p>
    </div>

    <div class="section">
      <strong>Positives</strong>
      <ul><li>Development strategy emphasizes partner-funded and externally supported programs to preserve internal capital</li><li>Near-term clinical data milestones expected for TPST-2003 (ongoing Phase 1 in China) with registrational Phase 2b targeted by end of 2026</li><li>TPST-1495 Phase 2 is expected to be NCI-funded with first patient enrollment targeted in Q1 2026, reducing internal cash burden</li><li>Amezalpat is described as Phase 3-ready with positive randomized Phase 2 data and global regulatory alignment</li><li>Pipeline expansion into in vivo CAR-T (TPST-4003) could provide a more scalable, patient-friendly modality if successful</li></ul>
    </div>

    <div class="section">
      <strong>Negatives</strong>
      <ul><li>Plans and timelines are contingent on partner funding and external support, which may not materialize as expected</li><li>Several programs are early-stage (preclinical or Phase 1), carrying high clinical and regulatory risk</li><li>Company acknowledges need for additional capital and potential going-concern risk in SEC filings</li><li>Forward-looking milestones and benefits are uncertain and subject to delays (site activation, enrollment, funding)</li><li>Outcome-dependent strategy increases execution risk if strategic partners withdraw or funding levels change</li></ul>
    </div>

    <div class="section">
      <a href="https://news.nuntiobot.com/article/73ca1615-7204-48dd-b5e7-36fb8370e376" target="_blank">Original Article</a>
    </div>

    <div class="small">TPST â€¢ TradersLink AI News</div>
  </div>
</body>
</html>